The crossroad of delirium, mania, and catatonia: A case series on delirious mania Authors: Riya Gangwal, Vaibhav Sunil Nawale, Varchasvi Mudgal, Rahul Mathur Published: 2025 ABSTRACT Background:Delirious mania (DM) is a rare, life-threatening neuropsychiatric syndrome marked by the simultaneous presence of manic excitement, catatonia, and fluctuating consciousness. Although described extensively in Western literature, Indian reports remain limited.Cases:Four patients admitted to a government mental hospital in Central India were retrospectively evaluated for clinical features, investigations, comorbidities, treatment, and outcomes. All had a prior diagnosis of bipolar disorder and presented with acute agitation, grandiosity, disorientation, and catatonic features; two had past DM episodes. Comorbid hypertension and metabolic disturbances were noted in two cases. All showed clinical improvement with lorazepam, sodium valproate, and atypical antipsychotics, while one required electroconvulsive therapy for full resolution. Symptom stabilization occurred within 7–14 days of targeted treatment. Ethical approval and informed consent procedures were duly followed.Conclusion:DM should be considered in bipolar patients presenting with catatonia and delirium. Early recognition and multimodal treatment, including electroconvulsive therapy (ECT) when needed, ensure favorable outcomes. INTRODUCTION Delirious mania (DM) is a severe neuropsychiatric syndrome marked by the simultaneous presence of manic symptoms, delirium, and catatonia. First described in classical European psychiatry by Calmeil, Bell, and Kraepelin, the condition is characterized by acute onset of grandiosity, psychomotor agitation, confusion, and catatonic signs such as rigidity, mutism, or excitement.[12] Although international estimates suggest that 15%–30% of patients hospitalized for acute mania may display features consistent with DM, the syndrome is frequently under-recognized and under-reported.[3] Diagnostic difficulty arises because its manifestations overlap extensively with hyperactive delirium, acute psychosis, malignant catatonia, and treatment-resistant mania. In India, the situation is further complicated by limited awareness, the burden of medical comorbidities, and delays in seeking psychiatric care.[1] Patients with bipolar affective disorder appear to be particularly vulnerable to developing DM. Standard antimanic treatment alone is often insufficient because the delirious and catatonic components require early identification and targeted intervention. Western literature consistently highlights DM as a psychiatric emergency requiring rapid evaluation and multimodal treatment approaches.[4] However, Indian literature remains sparse, and the condition is often misclassified as toxic encephalopathy, organic delirium, disorganized schizophrenia, or non-responsive mania.[56] Debate continues regarding the nosologically placement of DM; while some authors consider it part of the catatonia spectrum, others classify it as a severe variant of bipolar disorder.[7] Therapeutic strategies supported by existing evidence include the early use of benzodiazepines—particularly lorazepam—followed by mood stabilizers and atypical antipsychotics, with electroconvulsive therapy (ECT) reserved for cases that do not respond adequately to pharmacotherapy.[1891011] Previous Indian reports also emphasize that early lorazepam trials and timely initiation of ECT are often critical for successful outcomes.[12] The Institutional Review Board approved this retrospective case series. Written informed consent for publication was obtained from each patient, or from a legally authorized representative when capacity was impaired, with waivers granted where appropriate for retrospective data use. We describe four patients with DM, who were treated at a government mental hospital in Central India, emphasizing diagnostic challenges, treatment responses, and the importance of early recognition in resource-limited psychiatric settings. CASES Patient 1 Patient 1 was a 46-year-old man with a 15-year history of bipolar affective disorder (ICD-10 DCR). He presented with ten days of severe agitation, pressured speech, decreased sleep, grandiose delusions, and fluctuating disorientation worsening toward evening. MSE revealed inattention, distractibility, and limb rigidity. He was CAM-positive with admission scores of DRS-R-98 23/46, YMRS 36, and MMSE 22/30. Investigations were normal barring mild azotemia, which was promptly corrected. Initial valproate and olanzapine yielded minimal improvement over 2 weeks. On Day 14, lorazepam (2 mg BD) was introduced, leading to marked resolution of symptoms within 72 hours. By discharge on Day 21, CAM was negative, scores improved (DRS-R-98 6/46, YMRS 10), and he returned to baseline with tapered lorazepam. Patient 2 Patient 2, a 63-year-old man with hypertension and a six-year bipolar history (one prior DM episode), presented with a month-long history of irritability, severe confusion, agitation, tremors, and rigidity with evening worsening. Admission revealed hypertension, disorientation, and significant hyponatremia (Na+ 126 mEq/L), which was urgently corrected. Baseline scores were DRS-R-98 24/46, YMRS 34, and MMSE 20/30. Neuroimaging was normal. Valproate and aripiprazole showed limited effect. A mid-course BFCRS score of 11 prompted lorazepam initiation (2 mg BD). Within 2–3 days, orientation and interaction improved significantly. By discharge on Day 29, scores dropped (DRS-R-98 7/46, YMRS 12), achieving full recovery. Patient 3 Patient 3, a 47-year-old woman with a 12-year bipolar history and prior DM, presented with ten days of intense irritability, disorientation, grandiosity, rigidity, echolalia, and autonomic instability. Admission scores were DRS-R-98 26/46, YMRS 42, MMSE 18/30, and BFCRS 19. Extensive labs and brain CT excluded medical causes. An early lorazepam challenge was titrated to 16 mg/day alongside aripiprazole and quetiapine, but improvement was minimal over 2 weeks [cite: 45-47]. [cite_start] Due to the persistent delirious–catatonic picture, bilateral brief-pulse ECT was initiated on Day 15. Dramatic improvement occurred after the second session; by the sixth, symptoms resolved. At discharge (Day 28), scores were DRS-R-98 5/46 and YMRS 9, returning to premorbid functioning. Patient 4 Patient 4, a 55-year-old man with a 15-year bipolar history, presented with 40 days of worsening aggression, grandiosity, insomnia, fluctuating confusion, and rigidity. Admission scores were DRS-R-98 21/46, YMRS 35, and MMSE 21/30. Comprehensive workup (MRI, metabolic, toxicological) was normal. Initial valproate and olanzapine provided little benefit after two weeks. A BFCRS score of 15 prompted lorazepam (1 mg QID). Symptoms resolved gradually over the next 2 weeks. By discharge on Day 28, DRS-R-98 improved to 6/46 and YMRS to 11. He returned to premorbid functioning with slow lorazepam tapering. Across all cases, the diagnosis of DM was confirmed only after excluding organic causes and documenting fluctuating orientation with concurrent catatonic and manic features. All patients recovered fully, though one required ECT. DISCUSSION This case series [Table 1] highlights the classical clinical profile of DM and the diagnostic challenges it poses in real-world psychiatric settings. All four patients exhibited the characteristic triad of manic excitement, delirium, and catatonia. The fluctuating disorientation, agitation, grandiosity, hallucination-like experiences, rigidity, tremors, echolalia, and evening worsening seen in these cases closely align with descriptions in earlier literature.[2413] However, because these symptoms overlap with isolated delirium, functional psychosis, or severe mania, the diagnosis is often delayed, leading to prolonged morbidity. Table 1Summary of patients with delirious maniaCharacteristicsPatient 1Patient 2Patient 3Patient 4Age/Sex46/Male63/Male47/Female55/MaleDuration of bipolar disorder15 years6 years12 years15 yearsPast bipolar episodes (manic/depressive)~10 manic, 3 depressive6 manic, 2 depressives12 manic, 4 depressives10 manic, 2 depressivesPast delirious mania episodesNo previous DMOne past episodeOne past episodeNoneProminent symptoms at presentationAgitation, grandiosity, fluctuating orientation, rigidityConfusion, agitation, tremors, rigiditySevere irritability, disorientation, echolalia, rigidity, autonomic instabilityAggression, confusion, grandiosity, insomnia, generalized rigidityCatatonic features observedRigidity, excitementRigidity, upper-limb tremorsRigidity, echolaliaGeneralized rigidity, slurred speechTreatment before lorazepamSodium valproate + olanzapineSodium valproate + aripiprazoleAripiprazole + quetiapineSodium valproate + olanzapineLorazepam responseIntroduced Day 14; rapid response within 48–72 hIntroduced mid-course; significant improvement in 48–72 hHigh-dose (up to 16 mg/day) with minimal responseIntroduced Day 15; steady improvement over 1–2 weeksElectroconvulsive therapy (ECT)Not requiredNot requiredRequired (6 sessions); dramatic responseNot requiredConfusion Assessment Method (CAM)Positive → NegativePositive → NegativePositive → NegativePositive → NegativeDelirium Rating Scale–Revised-98 (baseline → discharge)23 → 624 → 726 → 521 → 6Young Mania Rating Scale (YMRS) (baseline → discharge)36 → 1034 → 1242 → 935 → 11Mini–Mental State Examination (MMSE) (baseline)22/3020/3018/3021/30Bush–Francis Catatonia Rating Scale (BFCRS)Not doneMid-course: 11Baseline: 19Mid-course: 15Time to symptom resolution7 days (post-lorazepam)7 days (post-lorazepam)14 days (post-ECT)14 days (post-lorazepam)OutcomeFull recoveryFull recoveryFull recoveryFull recovery Summary of patients with delirious mania Diagnosing DM remains difficult because neither the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) nor the International Classification of Diseases, Eleventh Revision (ICD-11) recognizes it as a distinct diagnostic entity. The diagnosis therefore depends on thorough bedside evaluation, exclusion of medical causes, and awareness of its distinct phenomenology. Differential diagnoses such as malignant catatonia, neuroleptic malignant syndrome, serotonin syndrome, alcohol or benzodiazepine withdrawal delirium, disorganized schizophrenia, thyrotoxicosis, and metabolic or infectious encephalopathies must be considered and ruled out systematically.[14] In our series, rigorous medical workup was essential, particularly in patients with hyponatremia or mild renal dysfunction, where delirium could have been misattributed to metabolic causes. The persistence of confusion and catatonia despite correction of abnormalities strengthened the diagnosis of primary psychiatric DM. Treatment response patterns in our patients underscore key principles in the management of DM. Lorazepam was consistently effective in rapidly relieving catatonic and delirious symptoms in 3 of the 4 patients. This responsiveness supports existing recommendations that benzodiazepines should be administered early, not only as treatment but also as a diagnostic aid in suspected catatonia.[12] In the fourth patient, despite high-dose lorazepam and adequate trials of antipsychotics and mood stabilizers, symptoms persisted until ECT was initiated. The dramatic improvement following ECT is consistent with literature emphasizing its role as a life-saving and rapidly effective intervention in refractory or severe cases of DM.[915] Taken together, the treatment outcomes in this series reaffirm that DM requires a multimodal approach and that ECT should not be delayed when benzodiazepines fail to produce adequate improvement. The presence of hypertension and metabolic abnormalities in some cases highlights the importance of thorough medical assessment in Indian settings. Comorbidities can complicate clinical presentation, mimic delirium, or limit medication choices. Furthermore, substance use disorders, although not seen in these patients, are highly prevalent among individuals with bipolar disorder and may precipitate catatonic or delirious states; thus, careful screening is always necessary.[16] Systemic challenges unique to Indian psychiatric services also affect the recognition and management of DM. These include the heavy patient load in government hospitals, delayed referrals due to stigma and reliance on traditional healers, limited availability of ECT in many districts, and variable access to neuroimaging and laboratory investigations. Such constraints may contribute to the under-recognition of DM and the potential misclassification of these cases as medically induced delirium, encephalopathy, or functional psychosis. In the absence of formal diagnostic criteria, Indian psychiatric centers may benefit from simplified protocols that include early administration of the Confusion Assessment Method, the Delirium Rating Scale–Revised-98, the Young Mania Rating Scale, and the Bush–Francis Catatonia Rating Scale. Rapid basic laboratory screening, early lorazepam trials when catatonia is evident, and timely consideration of ECT can substantially improve outcomes and reduce hospitalization duration. CLINICAL IMPLICATIONS DM should be considered in any patient with bipolar disorder, who presents with acute onset of fluctuating disorientation, severe agitation, and catatonic symptoms. Early recognition facilitates rapid initiation of lorazepam, mood stabilizers, and antipsychotics, while ECT becomes essential when pharmacotherapy fails. Excluding organic causes through comprehensive investigations is critical, particularly in settings with high burden of medical comorbidities. Improvement in awareness, training, and availability of ECT resources within Indian psychiatric services may significantly enhance outcomes for this potentially life-threatening condition. CONCLUSION DM represents a psychiatric emergency that requires prompt diagnosis and decisive, multimodal intervention. Our case series demonstrates that early recognition of the coexisting manic, delirious, and catatonic features—combined with timely use of lorazepam, mood stabilizers, and antipsychotics, and ECT whenever necessary—can lead to complete recovery. Greater awareness and structured diagnostic assessment protocols are urgently needed in Indian psychiatric practice to prevent misdiagnosis, shorten treatment delays, and optimize clinical outcomes. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Conflicts of interest There are no conflicts of interest.